Illumina (NASDAQ:ILMN) Reaches New 1-Year High Following Strong Earnings

Shares of Illumina, Inc. (NASDAQ:ILMN) hit a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $199.65 and last traded at $197.1860, with a volume of 298140 shares traded. The stock had previously closed at $194.82.

The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 30.54% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the previous year, the business earned $1.19 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ILMN shares. Leerink Partners upped their price target on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday, May 14th. Finally, TD Cowen increased their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $175.47.

Insiders Place Their Bets

In other news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares of the company’s stock, valued at approximately $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Illumina

Several hedge funds have recently bought and sold shares of ILMN. Capital World Investors increased its holdings in shares of Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp lifted its holdings in shares of Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after acquiring an additional 190,324 shares during the last quarter. WCM Investment Management LLC lifted its holdings in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC grew its position in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after acquiring an additional 130,139 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Up 0.0%

The firm has a market cap of $31.03 billion, a P/E ratio of 38.26, a PEG ratio of 3.03 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a 50 day moving average of $176.70 and a 200 day moving average of $147.24.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.